This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G11.0 | Special Copayment Reduction: V123 |
| B. Synonyms | Congenital nonprogressive cerebellar ataxia, nonprogressive congenital ataxia |
| C. Adult onset | Likelihood of first onset in adulthood very low — onset is at birth or in early childhood, with a nonprogressive course |
| 1. History | Process of establishing the concept of nonprogressive congenital ataxia, differentiation from cerebral palsy, development of genetic classification |
| 2. Causes | Cerebellar malformation, cerebellar hypoplasia, gene mutations (SPTBN2, ITPR1, etc.), cause unknown in some |
| 3. Genetics | Genetic heterogeneity, various modes of inheritance (autosomal recessive, dominant, X-linked), contribution of exome sequencing to diagnosis |
| 4. General epidemiology | A relatively common cause of pediatric ataxia, exact prevalence unclear, more frequent than progressive ataxia |
| 5. Pathophysiology | Cerebellar developmental disorder, abnormal formation of the cerebellar cortex and cerebellar white matter, defects in neuronal migration and differentiation |
| 6. Symptoms | Hypotonia, motor developmental delay, balance disorder, speech disorder, oculomotor abnormalities, possible accompanying cognitive impairment |
| 7. Signs | Signs of cerebellar ataxia (limb ataxia, gait ataxia, intention tremor), nystagmus, dysarthria |
| 8. Screening | Early imaging and gene panel testing when a cerebellar abnormality is suspected in a child with developmental delay |
| 9. Diagnosis | Diagnosis established by brain MRI assessment of cerebellar morphology, gene panel/exome sequencing, and observation of whether the condition progresses |
| 10. Treatment | No curative treatment, rehabilitation therapy (physical, occupational, speech therapy), seizure control, early educational intervention |
| 11. Prognosis | Nonprogressive course, some functional improvement possible, poor prognosis when accompanied by cognitive impairment or seizures |
| 12. Prevention | Genetic counseling, prenatal diagnosis, family planning support, early rehabilitation intervention |
| 13. References | Steinlin M. Dev Med Child Neurol 1998 and 9 other papers |
The concept of congenital nonprogressive ataxia (NPCA) was gradually established from the mid-20th century along with the development of pediatric neurology. Initially, children with motor developmental delay and balance disorders were often included in the category of cerebral palsy, but it was gradually recognized that nonprogressive ataxia of cerebellar origin should be distinguished from cerebral palsy. With advances in brain MRI technology since the 1990s, various cerebellar developmental abnormalities such as cerebellar hypoplasia and cerebellar cortical dysplasia could be identified radiologically, which contributed greatly to the etiologic classification of NPCA.
In 1998, Steinlin et al. reported 34 cases of nonprogressive cerebellar ataxia, systematizing the clinical and imaging features and analyzing the relationship between cerebellar morphologic abnormalities and clinical severity. With the introduction of exome sequencing technology after the 2000s, the genetic heterogeneity of this group of diseases began to become clear. Many genes, such as SPTBN2, ITPR1, GRM1, and ATCAY, were found to be associated with nonprogressive congenital ataxia. In 2021, a systematic proposal on the clinical classification and diagnostic approach to congenital ataxia was published internationally, contributing to standardization of diagnosis.
Currently, because of its very large clinical and genetic heterogeneity, this disease is recognized as a clinical syndrome with various etiologies rather than a single disease. As next-generation sequencing (NGS) technology and cerebellar developmental biology continue to advance, molecular classification is expected to become even more refined.
The causes of congenital nonprogressive ataxia can be broadly divided into cerebellar developmental abnormalities (cerebellar malformation/hypoplasia) and gene mutations. Cerebellar hypoplasia is a state in which the cerebellar lobes and cerebellar nuclei develop smaller than normal, and its cause may be genetic or prenatal injury (infection, hypoxia, hemorrhage). Structural abnormalities such as cerebellar cortical dysplasia and pontocerebellar hypoplasia are also included.
Among genetic causes, heterozygous mutations of SPTBN2 (beta-spectrin type 2) have recently been recognized as a relatively common cause, producing nonprogressive ataxia with very early onset. ITPR1 gene mutations are associated with SCA types 15/16, and heterozygous mutations can cause congenital cerebellar hypoplasia and nonprogressive ataxia. Mutations of GRM1 (metabotropic glutamate receptor 1) and ATCAY (caytaxin gene) have also been reported. In some, variants in brain development regulatory genes such as SOX2 and RELN are involved.
Non-genetic causes include prenatal infections (cytomegalovirus, congenital rubella), prenatal hypoxic-ischemic injury, preterm birth (cerebellar hemorrhage in premature infants), and prenatal exposure to toxic substances. Even in these cases, postnatal ataxia can follow a nonprogressive course. In a considerable proportion of all cases, the cause is not identified even after extensive testing including exome sequencing.
Congenital nonprogressive ataxia has very large genetic heterogeneity. Autosomal recessive, autosomal dominant, and X-linked modes of inheritance have all been reported. Even in sporadic cases with no family history, hereditary causes due to de novo mutations are increasingly being identified.
Representative genes of the autosomal dominant form are SPTBN2 and ITPR1. Heterozygous SPTBN2 mutations cause early-onset nonprogressive ataxia, and the gene locus overlaps with SCA type 5. Heterozygous ITPR1 mutations have a broad phenotypic spectrum, from congenital forms with cerebellar hypoplasia to adult-onset SCA types 15/16. For autosomal recessive forms, various genes such as ATCAY (Cayman ataxia), SLC1A3, VLDLR, and CA8 have been reported.
X-linked forms of ataxia also exist, associated with genes such as ATP2B3 and CASK. Overall, exome or genome sequencing-based testing finds a causative variant in about 40–60% of patients, but the rest still have an unknown cause. As gene discovery continues, the diagnostic yield is expected to improve further.
The exact prevalence of congenital nonprogressive ataxia is not yet well established. Epidemiological studies are limited because this disease is difficult to differentiate from cerebral palsy, is genetically highly heterogeneous, and lacks standardized diagnostic criteria. However, considering pediatric ataxia as a whole, nonprogressive forms are known to be more common than progressive forms.
The overall incidence of pediatric ataxia is estimated at about 26/100,000, and nonprogressive congenital ataxia accounts for a considerable portion of this. Cerebellar hypoplasia is found in a considerable proportion of patients with pediatric neurological disorders in brain MRI-based studies. Apart from X-linked forms, the sexes are generally affected equally. Both familial and sporadic cases exist, and autosomal recessive forms are more frequent in regions where consanguineous marriage is common.
In Korea, statistics on congenital nonprogressive ataxia alone are rare, and it is included in the registration figures for hereditary ataxia under Special Copayment Reduction code V123. This group of diseases is estimated to account for a considerable proportion of patients visiting pediatric neurology with early developmental delay and cerebellar ataxia as the chief complaint.
The pathophysiology of congenital nonprogressive ataxia is attributable to disruption of cerebellar development during fetal life. Because cerebellar development takes place from early pregnancy through several years after birth, genetic and environmental factors during this period can permanently affect cerebellar structure and function. Abnormalities in the differentiation, migration, and synapse formation of Purkinje cells and granule cells are the key pathogenic mechanisms.
SPTBN2 gene mutations cause deficiency of beta-III spectrin, a structural protein of cerebellar Purkinje cells, affecting cell stability and expression of the glutamate transporter (EAAT4). ITPR1 mutations cause dysfunction of the inositol 1,4,5-trisphosphate receptor (IP3R1), affecting calcium signaling and cell survival in Purkinje cells. GRM1 mutations cause abnormal cerebellar circuit formation through defective metabotropic glutamate signaling.
In cerebellar hypoplasia, cerebellar volume is reduced due to abnormalities of cell proliferation, migration, and programmed death (apoptosis), and the cerebello-pontine connections often fail to develop as well. Prenatal hypoxic-ischemic injury is known to selectively damage the posterior superior lobe of the cerebellum. What all these mechanisms have in common is that once cerebellar circuit formation has been irreversibly completed, it does not progress further, resulting in a nonprogressive course.
The first signs of congenital nonprogressive ataxia are infantile hypotonia and motor developmental delay. Delays in gross motor development, such as head control, sitting, standing, and walking, are prominent and are often misdiagnosed as cerebral palsy. The ataxia is nonprogressive, but as the child grows, new motor skills are learned slowly and difficulty maintaining balance persists.
Language developmental delay and dysarthria are common, owing to the cerebellum's involvement in language function. Cognitive impairment varies in degree, with a broad spectrum from mild intellectual disability to normal intelligence. Some degree of cognitive impairment accompanies it in about 30–50%. Seizures also occur in some and are associated with cerebellar hypoplasia or accompanying cortical abnormalities.
Oculomotor abnormalities such as nystagmus, strabismus, and impaired gaze fixation may appear. Behavioral problems, autism spectrum disorder traits, and attention-deficit/hyperactivity disorder (ADHD) sometimes accompany it. The overall pattern of symptoms can differ considerably depending on the causative gene and the location and extent of the cerebellar lesion. A nonprogressive course is characteristic, but in some patients functional improvement with growth is observed.
Standard signs of cerebellar ataxia are observed on neurological examination. In limb ataxia, dysmetria appears on the finger-nose test and heel-shin test. Gait ataxia is characterized by a wide-based gait, and tandem walking is impossible or unstable. Intention tremor is a characteristic cerebellar tremor whose amplitude increases as the target is approached.
Nystagmus may appear in the horizontal or vertical direction, and the direction varies with the location of damage in the cerebellar lobules. Dysarthria appears as slow and irregular speech rate, imprecise articulation, and difficulty with volume control (dysprosody). Hypotonia is prominent in infancy and partly improves with growth. Deep tendon reflexes may be decreased or normal.
Developmental tests (Bayley, K-WISC, etc.) are needed to assess cognitive function. In the form of cerebellar cognitive affective syndrome (CCAS), executive dysfunction, impaired spatial cognition, impaired language function, and difficulty with emotional regulation may accompany it. The absence of pyramidal signs (spasticity, Babinski) or sensory abnormalities on overall neurological examination is characteristic of pure cerebellar ataxia, and when accompanying signs are present, a complex form or another diagnosis should be considered.
Screening for congenital nonprogressive ataxia is performed mainly in children presenting with developmental delay. When there is generalized hypotonia in infancy, gross motor developmental delay, or signs of ataxia of cerebellar origin, brain MRI is performed immediately to evaluate for cerebellar structural abnormalities. Brain MRI is essential for differentiating cerebellar hypoplasia, cerebellar malformation, pontocerebellar hypoplasia, and the like.
Genetic testing should be performed early in all patients in whom a genetic cause is suspected. In current practice, gene panel testing including cerebellar ataxia-associated genes or clinical exome sequencing is used as the standard test. Family history and parental genetic testing (trio analysis including parental exomes) increase the detection rate of de novo variants.
Metabolic screening tests (blood amino acids, organic acids, lactate, ammonia, uric acid, thyroid function) are performed early to exclude ataxia due to metabolic disease. Electrophysiological tests (nerve conduction studies, visual, auditory, and somatosensory evoked potentials) help evaluate accompanying neurological abnormalities. Follow-up clinical evaluation at 6-month to 1-year intervals is needed to confirm a nonprogressive course.
The diagnosis of congenital nonprogressive ataxia is made by integrating clinical, imaging, and genetic information. The core diagnostic criteria are cerebellar ataxia with onset at birth or in early childhood and a nonprogressive course. Confirming a nonprogressive course requires follow-up of at least 6–12 months, and the absence of progression must be confirmed by objective clinical evaluation.
Brain MRI is the most important test for evaluating cerebellar morphologic abnormalities. It differentiates cerebellar hypoplasia, cerebellar cortical dysplasia, pontocerebellar hypoplasia (PCH), Dandy-Walker malformation, Joubert syndrome, and the like. MRI findings may be normal, so normal imaging does not exclude the diagnosis. High-resolution MRI and cerebellum-specific sequences help with diagnosis.
For genetic testing, cerebellar ataxia gene panels, clinical exome sequencing, or genome sequencing are used. Parental trio analysis is advantageous for detecting de novo variants. Metabolic tests exclude metabolic causes such as biotin or vitamin E deficiency, congenital disorders of glycosylation (CDG), and mitochondrial disease. As differential diagnoses, ataxic cerebral palsy, Rett syndrome, and various progressive ataxias (cases that merely appear nonprogressive early on) should be considered.
There is currently no curative treatment for congenital nonprogressive ataxia, and specific treatments according to the causative gene have mostly not been developed. The core of treatment is maximizing function through early rehabilitation therapy and managing accompanying symptoms.
Physiotherapy is started early with the aims of muscle strengthening, balance training, and gait improvement. In cerebellar ataxia, proprioceptive training, trunk stabilization exercises, and aquatic therapy are effective. Occupational therapy aims to improve fine motor function and increase independence in activities of daily living. Speech therapy intervenes early for dysarthria and language developmental delay. Assistive devices (ankle-foot orthoses, walkers, etc.) help improve mobility.
When seizures accompany it, anticonvulsants are used. For nystagmus accompanying cerebellar ataxia, clonazepam and gabapentin show some effect. For cognitive impairment, early special education and cognitive rehabilitation are recommended. Acetazolamide and 4-aminopyridine have been reported to be effective in some types of cerebellar ataxia, but evidence in the congenital nonprogressive form is limited. Family support and psychosocial support are also important components of treatment.
The key prognostic feature of congenital nonprogressive ataxia is its nonprogressive course. The ataxia itself does not worsen, and in many patients motor function partly improves with growth and rehabilitation therapy. Most patients survive into adulthood, and with appropriate support, a considerable level of independent living is possible.
The main factors affecting prognosis are the presence and degree of cognitive impairment, whether seizures accompany it, and the degree of language development. When cognitive impairment is severe, there are great difficulties in education and social integration. Uncontrolled seizures have an additional adverse effect on cognitive and behavioral development. The extent and degree of cerebellar hypoplasia show a certain correlation with motor prognosis.
Active early rehabilitation intervention is known to significantly improve long-term functional outcomes. After school age, social participation is promoted through special education and transition services. Life expectancy is generally close to normal unless comorbidities (severe seizures, aspiration pneumonia, malnutrition, etc.) are present. When the genetic cause is clear, genetic counseling provides risk assessment for siblings and family planning support.
The approach to prevention of congenital nonprogressive ataxia differs according to the cause. When a genetic cause is identified, genetic counseling is used to assess the recurrence risk within the family and to discuss the possibility of prenatal diagnosis or preimplantation genetic testing (PGT-M) in future pregnancies. In autosomal recessive forms, each parent is a carrier, and the recurrence risk is 25%. In autosomal dominant de novo forms, the theoretical recurrence risk is low, but germline mosaicism cannot be excluded.
In cases due to prenatal causes (prematurity, hypoxic injury, infection), management of obstetric risk factors, prevention of prenatal infection (rubella vaccination, prevention of cytomegalovirus infection), and efforts to prevent preterm birth are important. Appropriate neonatal intensive care to prevent cerebellar injury in preterm infants has preventive significance.
From a general prevention perspective, avoiding exposure to alcohol and toxic drugs during pregnancy and folic acid supplementation help prevent central nervous system developmental abnormalities. Because early diagnosis and early rehabilitation intervention improve long-term functional outcomes, active screening of children with developmental delay and early referral to specialists are key to improving prognosis.